Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1701 plus gemcitabine and nab-paclitaxel in first-line metastatic pancreatic cancer
CTR20202208Phase 2Completed
- Sponsor
- Hengrui Therapeutics
- Start
- Nov 2020
- Modality
- Fc-Fusion Proteins → Carrier/Scaffold Proteins → Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
A Phase 2 trial of retlirafusp alfa in pancreatic cancer (PC), sponsored by Hengrui Therapeutics. Started Nov 2020; status: completed.
02
Drugs
retlirafusp alfa
03
Conditions
pancreatic cancer (PC)
Beyond the preview
Go deeper on CTR20202208.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20202208.